Livia Lenzini1, Giacomo Rossitto1, Giuseppe Maiolino1, Claudio Letizia1, John W Funder1, Gian Paolo Rossi1. 1. Department of Medicine-DIMED (L.L., G.R., G.M., G.P.R.), Clinica dell'Ipertensione Arteriosa, University of Padua, Italy; Department of Internal Medicine and Medical Specialties (C.L.), University of Rome 'Sapienza', Rome, Italy; and The Hudson Medical Research Institute (J.W.F.), Clayton 3168, Australia.
Abstract
CONTEXT: Due to selection biases and inadequate statistical power, individual studies may fail to identify the clinical features of patients with an aldosterone-producing adenoma (APA) harboring KCNJ5 mutations. When this failure occurs, meta-analysis can provide significant outcome data. OBJECTIVE: The objective was to determine the clinical features of these APA patients. DESIGN: We systematically searched the PubMed, Scopus, Web of Science, and Cochrane databases library in January 2015 applying the Population, Intervention, Comparison, and Outcome (PICO) strategy. The standardized differences in mean and corresponding 95% confidence interval of continuous variables were computed by random-effects modeling. SETTING: We performed a meta-analysis of all available studies on somatic KCNJ5 mutations in APA. PATIENTS: We could identify 13 studies that recruited 1636 patients (age 49 ± 4 years; 55% females). MAIN OUTCOMES AND MEASURES: Differences between APA with and without KCNJ5 mutations in gender, plasma renin activity, plasma aldosterone, tumor size, serum potassium, and blood pressure were investigated. RESULTS: The overall prevalence of KCNJ5 mutations was 43% (range = 12-80%). Their rate was lower (P < .003) in the studies done in Europe, the United States, and Australia (35%) than in Japan and China (63%); it correlated (r = 0.60, P = .029) with the mean daily urinary sodium excretion. Compared with the wild-type, the mutated APA patients were younger (45 ± 3 vs 52 ± 5 yrs), had higher plasma aldosterone (42 ± 8 vs 33 ± 8 ng/dl), larger tumors (16.1 ± 6.4 versus 14.9 ± 7.4 mm), and were more often females (67% vs 44%) (all P < .05). CONCLUSIONS: Meta-analysis showed that more pronounced hyperaldosteronism, young age, female gender, and larger tumors are the phenotypic features of APA patients with KCNJ5 mutations. No significant differences in blood pressure and serum K(+) was found, which suggests that these clinical features do not help in identifying mutated APA patients.
CONTEXT: Due to selection biases and inadequate statistical power, individual studies may fail to identify the clinical features of patients with an aldosterone-producing adenoma (APA) harboring KCNJ5 mutations. When this failure occurs, meta-analysis can provide significant outcome data. OBJECTIVE: The objective was to determine the clinical features of these APA patients. DESIGN: We systematically searched the PubMed, Scopus, Web of Science, and Cochrane databases library in January 2015 applying the Population, Intervention, Comparison, and Outcome (PICO) strategy. The standardized differences in mean and corresponding 95% confidence interval of continuous variables were computed by random-effects modeling. SETTING: We performed a meta-analysis of all available studies on somatic KCNJ5 mutations in APA. PATIENTS: We could identify 13 studies that recruited 1636 patients (age 49 ± 4 years; 55% females). MAIN OUTCOMES AND MEASURES: Differences between APA with and without KCNJ5 mutations in gender, plasma renin activity, plasma aldosterone, tumor size, serum potassium, and blood pressure were investigated. RESULTS: The overall prevalence of KCNJ5 mutations was 43% (range = 12-80%). Their rate was lower (P < .003) in the studies done in Europe, the United States, and Australia (35%) than in Japan and China (63%); it correlated (r = 0.60, P = .029) with the mean daily urinary sodium excretion. Compared with the wild-type, the mutated APA patients were younger (45 ± 3 vs 52 ± 5 yrs), had higher plasma aldosterone (42 ± 8 vs 33 ± 8 ng/dl), larger tumors (16.1 ± 6.4 versus 14.9 ± 7.4 mm), and were more often females (67% vs 44%) (all P < .05). CONCLUSIONS: Meta-analysis showed that more pronounced hyperaldosteronism, young age, female gender, and larger tumors are the phenotypic features of APA patients with KCNJ5 mutations. No significant differences in blood pressure and serum K(+) was found, which suggests that these clinical features do not help in identifying mutated APA patients.
Authors: Michael Stowasser; Martin Wolley; Aihua Wu; Richard D Gordon; Julia Schewe; Gabriel Stölting; Ute I Scholl Journal: Curr Hypertens Rep Date: 2019-04-04 Impact factor: 5.369
Authors: Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke Journal: Curr Hypertens Rep Date: 2019-09-03 Impact factor: 5.369
Authors: Yuhong Yang; Celso E Gomez-Sanchez; Diana Jaquin; Elke Tatjana Aristizabal Prada; Lucie S Meyer; Thomas Knösel; Holger Schneider; Felix Beuschlein; Martin Reincke; Tracy Ann Williams Journal: Hypertension Date: 2019-08-26 Impact factor: 10.190
Authors: Teresa M Seccia; Brasilina Caroccia; Elise P Gomez-Sanchez; Paul-Emmanuel Vanderriele; Celso E Gomez-Sanchez; Gian Paolo Rossi Journal: Hypertension Date: 2017-09-25 Impact factor: 10.190
Authors: Crystal D C Kamilaris; Fady Hannah-Shmouni; Constantine A Stratakis Journal: Best Pract Res Clin Endocrinol Metab Date: 2020-05-23 Impact factor: 4.690
Authors: Ute I Scholl; James M Healy; Anne Thiel; Annabelle L Fonseca; Taylor C Brown; John W Kunstman; Matthew J Horne; Dimo Dietrich; Jasmin Riemer; Seher Kücükköylü; Esther N Reimer; Anna-Carinna Reis; Gerald Goh; Glen Kristiansen; Amit Mahajan; Reju Korah; Richard P Lifton; Manju L Prasad; Tobias Carling Journal: Clin Endocrinol (Oxf) Date: 2015-09-23 Impact factor: 3.478